Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + dexanabinol
- Development stage
- Discontinued
- Lead developer
- SOL Global Investments Corp.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A proprietary oral combination of cannabidiol (CBD) and the synthetic cannabinoid dexanabinol (HU-211) developed for the treatment of traumatic brain injury (TBI) and concussion. The therapy was initially developed through a collaboration between Scythian Biosciences and the University of Miami Miller School of Medicine. The mechanism of action involves CBD-mediated activation of receptors that trigger cellular repair and dexanabinol-mediated NMDA receptor antagonism to prevent calcium accumulation and neuroinflammation. While pre-clinical rodent studies showed improved cognitive function post-injury, development stalled after Scythian Biosciences (rebranded as SOL Global Investments) pivoted away from biotechnology and planned to spin off the program into Impact Biosciences.
- Other names
- CBD + dexanabinolCBD + HU-211
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))NMDAR (Glutamate receptor ionotropic, NMDA)FAAHPPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on cannabidiol + dexanabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + dexanabinol.